Department of Histopathology, The University of Nottingham and the Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK.
Department of Histopathology, St Vincent's University Hospital, University College, Dublin, Ireland.
Histopathology. 2021 Apr;78(5):759-771. doi: 10.1111/his.14290. Epub 2020 Dec 16.
Although rare, malignant sarcomatoid breast tumours without evidence of epithelial differentiation comprise a diagnostic challenge with management implications. Earlier studies have generally considered these to be primary breast sarcomas; however, supporting evidence is lacking and management remains variable. This study aimed to provide an evidence-based approach to improve the consistency of diagnosis and management for such cases.
A large series (n = 140) of metaplastic breast carcinoma (MBC) diagnosed in Nottingham over 18 years was analysed. Only cases with available data on immunohistochemical expression of cytokeratins (CKs) were included. The prevalence and pattern of expression for various CKs were assessed and details of tumours negative for CKs were collected. A diagnostic approach based on our experience is provided. Forty-seven cases (34%) showed foci of conventional type invasive breast carcinoma or ductal carcinoma in situ (DCIS), while 93 cases (66%) were diagnosed as MBC based on morphology and/or CK expression. Ninety-seven cases (69%) were negative for one or more CKs, with 18 cases (13%) negative for five or more CKs. Eight cases (6%) lacked expression of all CKs tested. Further examination showed evidence of carcinomatous nature in five cases, and three were diagnosed as MBC following extensive diagnostic work-up and based on our experience.
This study suggests that MBC represents a spectrum of neoplasms, with some lacking CK expression. Sarcomatoid neoplasms of the breast lacking evidence of carcinomatous morphology and CK expression may represent an extreme end of differentiation that can be considered as carcinomas rather than sarcomas for management purposes (following extensive work-up).
尽管罕见,但是缺乏上皮分化证据的恶性肉瘤样乳腺肿瘤在诊断上具有挑战性,并对治疗有影响。先前的研究通常认为这些是原发性乳腺肉瘤,但是缺乏支持证据,治疗仍存在差异。本研究旨在提供一种循证方法,以提高此类病例诊断和治疗的一致性。
对诺丁汉 18 年来诊断的大量(n=140)乳腺化生性癌(MBC)进行了分析。仅纳入了具有细胞角蛋白(CKs)免疫组织化学表达数据的病例。评估了各种 CK 的表达频率和模式,并收集了 CK 阴性肿瘤的详细信息。提供了基于我们经验的诊断方法。47 例(34%)显示常规型浸润性乳腺癌或导管原位癌(DCIS)的病灶,而 93 例(66%)基于形态学和/或 CK 表达诊断为 MBC。97 例(69%)CK 呈阴性,18 例(13%)CK 呈阴性 5 种以上。8 例(6%)缺乏所测试的所有 CK 的表达。进一步检查显示 5 例有癌性特征的证据,3 例经过广泛的诊断性检查,并基于我们的经验诊断为 MBC。
本研究表明,MBC 代表了一组肿瘤,其中一些缺乏 CK 表达。缺乏癌形态和 CK 表达的乳腺肉瘤样肿瘤可能代表了分化的极端,为了治疗目的(在进行广泛的检查后),可以将其视为癌而不是肉瘤。